Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1][2] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.[3]
Combination of | |
---|---|
Aripiprazole | Atypical antipsychotic |
Sertraline | Selective serotonin reuptake inhibitor |
Clinical data | |
Other names | ASC-01 |
Routes of administration | By mouth |
Legal status | |
Legal status |